# Paricalcitol in Treating Patients With Myelodysplastic Syndrome

> **NCT00064376** · PHASE2 · COMPLETED · sponsor: **Cedars-Sinai Medical Center**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** paricalcitol

## Key facts

- **NCT ID:** NCT00064376
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** — (—)
- **Last updated:** 2018-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064376, "Paricalcitol in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00064376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*